A Biotech VC’s Prescription For What Ails Pharma

Momentum is building to do something about high drug prices — but what? In Washington, a commonality among proposals from both sides of the aisle is that they’re all likely to hit pharma’s bottom line — and in response, many in pharma have invoked the sacrosanct mantle of “innovation” to combat any attempts to rein in drug spending.